Sam Bankman-Fried Estimates Coinbase Is Actually Losing $3B Per Year

Sam Bankman-Fried, CEO of cryptocurrency exchange FTX, believes that Coinbase Global Inc’s (NASDAQ: COIN) actual revenue may be different from what is presented in its earnings report.

Sam Bankman-Fried, CEO of cryptocurrency exchange FTX, believes that Coinbase Global Inc’s (NASDAQ:COIN) actual revenue may be different from what is presented in its earnings report.

What Happened: In a series of tweets, Bankman-Fried said that the cryptocurrency exchange’s “real revenue” from transactions was likely closer to $650 million.

“That leads to a loss of roughly $700m, plus another $400m from impairment,” he said.

“My guess is the vast majority of the expenses are coming from payroll/bonuses/etc. here.”

After accounting for stock-based compensation paid to the exchange’s 5,000 plus employees, the FTX chief estimated that Coinbase’s real net revenue was around $2.5 billion, while expenses from employee compensation and other areas were a cumulative $5.5 billion.

“It’ll be interesting to see the impact of their recent headcount changes on upcoming earnings,” wrote Bankman-Fried, who estimates that the company is losing around $3 billion a year.

He also pointed to macro-sentiment that could potentially swing in Coinbase’s favour in the months to come.

“Remember: Coinbase is more sentiment-dependent than FTX! Large upside in a recovery,” he said.

Coinbase shares fell 10.55% on Tuesday after it reported revenue of $802.6 million, missing the Street estimate of $830.5 million. The stock was trading 5.45% lower after hours.

Meanwhile, the crypto market saw a 3.77% decline to $1.08 trillion over the last 24 hours. At press time, Bitcoin (CRYPTO: BTC) was trading at $22,895, down 3.5% and Ethereum (CRYPTO: ETH) was trading at $1,682, down 4.8% as per data from Benzinga Pro.

Photo courtesy: Cointelegraph on Wikimedia

Total
0
Shares
Related Posts
Read More

Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home LSD microdosing trial in patients with Major Depressive Disorder (MDD).

CMPS